BridgeMD
New treatment option for Hyperuricemia With or Without Gout
Official title Tart Cherry Citrate Effervescent Tablet for Urate-Lowering Therapy in Participants With Asymptomatic Hyperuricemia
ClinicalTrials.gov ID: NCT07613138
What this study is testing
- What it's testing
- The goal of this clinical trial is to learn whether tart cherry citrate effervescent tablets can lower uric acid levels in people with asymptomatic hyperuricemia (high uric acid levels without gout symptoms). The main question it aims to answer is: Does taking tart cherry citrate effervescent tablets lower uric acid levels more effectively than taking a placebo (inactive) tablet, when both groups also receive lifestyle guidance?
- Time commitment: about 24 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Aged 18 to 65 years, regardless of sex;
- Meet the diagnostic criteria for primary hyperuricemia, with serum urate levels between 420 μmol/L and 540 μmol/L (for those without comorbidities)...
- Participants with asymptomatic hyperuricemia who have not previously received urate-lowering therapy and have no history of acute gout flares;
- Voluntarily participate in the study and provide written informed consent.
You likely can't join if
- Known allergy to any of the study medications, food products, or their components; current allergies; or known hypersensitivity;
- Active liver disease or cirrhosis, or liver dysfunction with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \>2 times the...
- Acute infection or active gastrointestinal ulcers;
- History of thyroid dysfunction;
- Estimated glomerular filtration rate (eGFR) \<60 mL/min;
- Severe cardiac diseases, such as decompensated heart failure (NYHA class III or IV), unstable angina, or a history of myocardial infarction within...
See the full eligibility criteria
- Aged 18 to 65 years, regardless of sex;
- Meet the diagnostic criteria for primary hyperuricemia, with serum urate levels between 420 μmol/L and 540 μmol/L (for those without comorbidities) or between 420 μmol/L and 480 μmol/L (for those with at least one of...
- Participants with asymptomatic hyperuricemia who have not previously received urate-lowering therapy and have no history of acute gout flares;
- Voluntarily participate in the study and provide written informed consent.
- Known allergy to any of the study medications, food products, or their components; current allergies; or known hypersensitivity;
- Active liver disease or cirrhosis, or liver dysfunction with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \>2 times the upper limit of normal (ULN);
- Acute infection or active gastrointestinal ulcers;
- History of thyroid dysfunction;
- Estimated glomerular filtration rate (eGFR) \<60 mL/min;
- Severe cardiac diseases, such as decompensated heart failure (NYHA class III or IV), unstable angina, or a history of myocardial infarction within the previous 12 months;
- Renal cysts, medullary sponge kidney, or other obstructive nephropathies;
- Rheumatoid arthritis requiring treatment or arthropathies due to other causes;
- Current use of medications that affect urate levels, including febuxostat, allopurinol, benzbromarone, probenecid, azathioprine, 6-mercaptopurine, cyclosporine, cyclophosphamide, pyrazinamide, sulfamethoxazole...
- Secondary hyperuricemia due to hematologic disorders, renal diseases, or radiotherapy/chemotherapy for malignancies;
- Brain disorders with impaired judgment, or mental disorders that preclude cooperation;
- Alcohol or substance abuse;
- Participation in another clinical trial within the three months prior to screening;
- Malignancy or active tuberculosis;
- Presence of other concurrent conditions that, in the investigator's judgment, may affect the how well it works evaluation or result in poor compliance;
- Use of glucocorticoids;
- Any other reason that, in the investigator's judgment, makes the participant unsuitable for enrollment in this trial.
The study team makes the final eligibility decision.
Where it's taking place
- Xiamen, Fujian, China
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 24 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Xiamen, Fujian, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.